Research

Infectious Disease Research

SUNY Upstate Medical University Public Health and Preventive Medicine Grand Rounds 10/22/2015

Climate Drivers of Emerging Infectious Diseases: Research Advances in Ecuador presented by Anna Stewart Ibarra, PhD MPA 

View the presentation

Expand all

Present Projects

Title: Phase one, Open Label, Assessment of a Dengue-1-Virus-Live Virus Human Challenge-       (DENV-1-LVHC) Virus Strain

2018-

PI Investigator: Dr.Timothy P. Endy

Study Coordinator: Michelle Klick, LPN, CCRP

Purpose: The purpose of this research study is to determine if we can develop this weakened dengue virus to safely produce mild dengue symptoms in a human. We want a weakened dengue virus so in the future, we can use it to test whether or not new vaccines or drugs for dengue actually work.

This study is supported by the United States Army Medical Research and Materiel Command (USAMRMC).   

___________________________________________________________________________________

 

Title: Personalized Antiplatelet Secondary Stroke PRevenTion (PASSPoRT). Randomized, Phase II, Open Label, Trial in Ischemic Stroke Survivors Age 18 years and older.

2017-

PI Investigator: Dr. Karen C Albright

Study Coordinator: Kelly Bartlett, BS, CCRP

Purpose: The purpose of this study is to establish the safety and feasibility of using a personalized medicine approach to select a blood thinner (also called antiplatelet drug) based on a person's specific characteristics (such as: age, diabetes status) and genetic information instead of prescreening a blood thinner by the usual standard care (one size fits all approach). This is important to doctors who care for stroke patients because we prescribe these medications to prevents recurrent stroke. All medicines used in this study is FDA approved.

This study is supported by SUNY Upstate Medical University and the National Institute of Health.

___________________________________________________________________________________

Title: Effects of cART Long-Term Exposure on Neuronal Function and Brain Microstructure in HIV Infected Individuals ART Naive Starting cART.

2016-

PI Investigator: Dr. Elizabeth Asiago-Reddy

Study Coordinator: Kelly Bartlett, BS, CCRP

Purpose: The Purpose of this study is to determine what effects combination antiretroviral therapy has on brain function. there are concerns that long-term exposure to combination antiretroviral therapy may predispose the brain to injury especially in the older HIV infected subjects. The results from this study may provide further knowledge on how to best minimize the risks of brain injury due to HIV infection itself and those caused by the HIV drugs.

This study is supported by the University of Rochester and the National Institute of Mental Health.

___________________________________________________________________________________

 

Title: Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed.

2016-

PI Investigator: Dr. Elizabeth Asiago-Reddy

Study Coordinator: Kelly Bartlett, BS, CCRP

Purpose: The purpose of this study is to determine the efficacy, safety and tolerability of two approved medicines, dolutegrair (DTG) plus lamivudine (3TC) taken together, compared with subjects taking their current tenofovir alafenamide (TAF)-based regimen (TBR) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed.

This study is supported by ViiV Healthcare, a global specialist HIV company, and GlaxoSmithKline (GSK).

___________________________________________________________________________________

Title: The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term non-progression of HIV infection.

2016-

PI Investigator: Dr. Elizabeth Asiago-Reddy

Study Coordinator: Kelly Barlett, BS, CCRP

Purpose: The purpose of this study is to determine if people with HIV who have certain antibody responses in their blood are more likely to maintain adequate CD4 counts off of therapy. We want to learn if the presence of certain antibodies in the blood are more common in individuals infected with HIV who do not show progression of their disease (indicated by maintenance of adequate CD4 levels off therapy).

This study is supported by the University of Buffalo.

___________________________________________________________________________________

 

 

Title: A Multicenter Study to Assess the Clinical Safety and Treatment Strategy of using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 weeks in Virologically Suppressed Subjects with CCR5-tropic HIV-1 infection.

2016-

PI Investigator: Dr. Elizabeth Asiago Reddy

Study Coordinator: Kelly Barlett, BS, CCRP

Purpose: The purpose of this study is to determine if the study product, PRO 140, is safe and if it works to suppress viral load in HIV-1 patients in combination with FDA approved antiretroviral regimens. The safety and effectiveness of PRO 140 has been previously evaluated in 17 people in previous approved by the U.S. Food and Drug Administration (FDA). The results of these studies will be used to design future studies to try to better understand how to design and implement treatment regimens that will be most successful in treating HIV-1 infection.

This study is supported by CytoDyn.

___________________________________________________________________________________

 

Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial, followed by Single-Arm Treatment of PRO 140 in Combination with Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects.

2016-

PI Investigator: Dr. Elizabeth Asiago Reddy

Study Coordinator: Kelly Barlett, BS, CCRP

Purpose The purpose of this study is to find out how safe and how well the study product, PRO 140 monotherapy works in comparison to the combination of oral antiretroviral drugs for the maintenance of viral suppression in HIV-1 patients.

This study is supported by CytoDyn.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                                       

 

 

 

 

 

Past Projects

Title: Exploration of immunologic mechanisms of immune interference and/or cross-neutralizing immunity following administration schedules with CYD tetravalent dengue vaccine.

2012-2016

PI: Mark Polhemus

Purpose: The major goals of this project are a Phase II trial of a dengue vaccine.

This project is supported by the Department of Defense.


Title: Immunogenicity of a two vs. three dose, Intradermal (ID) vs. Intramuscular (IM) administration of a licensed rabies vaccine for pre-exposure vaccination.

PI: Mark Polhemus

2012-2015

Purpose: The major goals of this project are evaluation of different dosing regimens of a licensed rabies vaccine for use in pre-exposure prevention of disease.

This project is supported by the Department of Defense-Military Vaccine Agency.


Title: The Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-Exposure Prophylaxis.

PI: Mark Polhemus

2012-2015

Purpose: The major goals of this project are evaluation of the effect of antimalarial drugs on the immune response and development of protective antibodies with standard rabies vaccination.

This project is supported by the Department of Defense-Military Vaccine Agency.


Title: Capacity strengthening in Ecuador Year 2: Partnering to improve surveillance of febrile vector-borne diseases.

PI and Co-PIs: Mark Polhemus, Timothy Endy, Anna Stewart Ibarra

2012-2015

Purpose: The major goals of this study are strengthening of the surveillance efforts in Ecuador and development of a research platform to evaluate climate, vector, and disease impact on the country.

This project is supported by the Department of Defense-Global Emerging Infections Surveillance.


Title: Dengue virus circulation, evolution, virus-vector, and virus-host interactions in Kamphaeng Phet Province, Thailand.

PI: Timothy Endy

2011-2015

Purpose: The major goal of this study is to use geographic information system analysis of the microevolution of dengue viruses.

This project is supported by the Department of Defense-Telemedicine and Advanced Technology Research Center.


Title: Using advanced proteomics to understand vaccine induced immunogenicity.

PI: Timothy Endy

2012-2015

Purpose: The major goals of this project are utilizing proteomics to identify unique biomarkers after dengue vaccination for induced protective immunogenicity.

This project is supported by the Department of Defense-Military Infectious Diseases Research Program.


Title/Purpose: Ecuador-U.S.. collaboration to investigate interactions among infectious diseases and nutrition

PI: Anna Stewart

2014-2016

This project is supported by the National Secretary of Higher Education, Science, Technology and Innovation of Ecuador.<


Title/Purpose: Developing an operational research framework to assess local flood response capacities: A case study of rural coastal community in Ecuador

PI: Anna Stewart

2014-2015

This project is supported by the Intramerican Institute for Global Change Research.


Title/Purpose: Interactions among climate variability and the occurrence of Harmful Algal Blooms (HABs) and their impact on human health in an estuarine-coastal gradient (Guayaquil-Santa Elena)

2015-2017

PI: Anna Stewart

This project is supported by Escuela Superior Politcenia del Litoral.

 

Title: Evaluating the potential use of oceanographic information and remotely sensed algal blooms to predict risk of Cholera and other water sensitive diseases.

PI: Mark Polhemus, Timothy Endy, Anna Stewart Ibarra

2013-2014

Purpose: The major goals of this study are evaluating a novel strategy for cholera surveillance in environmental waters, and public health capacity building in Ecuador, including development of an intensive geospatial research methods course.

This project is supported by the Department of Defense-Global Emerging Infections Surveillance.


Title: Impact of subcutaneous versus intramuscular administration of Inviragen’s live attenuated dengue vaccine on safety and immunogenicity.

PI: Mark Polhemus

2012-2014

Purpose: The major goals of this project are a Phase II trial of a dengue vaccine.

This project is supported by the Department of Defense-Military Vaccine Agency.


Title: Dengue virus diversity in Northern Thailand.

PI: Timothy Endy

2008-2014

Purpose: The major goal of this project is a long-term study to determine dengue genetic diversity and the ecologic effects of a live-attenuated tetravalent dengue vaccine.

This project is supported by the National Institute of Allergy and Infectious Disease.

 

 


Top